|
|
|
International Clinical Trials
|
Acceleration of the integration of mobile health (mHealth) technologies into clinical trial operations is expected to be the catalyst for the adoption of disruptive research platforms with capabilities to overcome barriers in both clinically mature and emerging markets. While mHealth applications of smart devices, wearable biometric sensors, and telemedicine enable health monitoring, data collection, and patient communications have been around for some time. Despite this, their widespread use in clinical research should still be considered in its infancy. We continue to see the fast development of integrated mHealth platforms that have the potential to turn the traditional research model on its head – taking studies to patients rather than bringing patients into site-based studies. Powered by Big Data and connected across patients, researchers, and caregivers, emerging mHealth platforms will expand research participation, reduce costs, and integrate research with treatment in new models of personalised medicine based on real-world evidence.
The mHealth Disruption Four foundational trends are driving 21st century biomedical research:
- Globalisation is expanding drug development into the emerging markets of Africa, Asia, and Latin America
- Big Data is being harnessed to understand disease impacts at the population level and support evidence-based medical practice
- Real-world evaluation is extending the continuum from traditional randomised clinical trials to new research models that assess real-world outcomes
- Personalised medicine is advancing with targeted therapies tailored to smaller populations and the growth of patientcentric research
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine
VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ --
TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have
entered into a manufacturing agreement to produce THEVAX HBV vaccine for
first-in-human clinical trials.
More info >> |
|
 |
White Papers |
 |
|
The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation
BioPharmaSpec
1. Introduction
As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >> |
|
 |
Industry Events |
 |
HPLC 2018
29 July - 2 August 2018, Washington Marriott Wardman Park, Washington, DC, USA
Are you interested in mass spectrometry, chromatography, or
electrophoresis? Are you solving complex analytical problems? Are you looking
for a conference with strong scientific content, a robust program,
presentations by world renowned experts, lectures by young scientists, courses
offering great training opportunities, tutorials, panel discussions, vendor
technical workshops, best poster competition, and a major exposition showcasing
new product launches and innovative products? Mark your calendar to attend HPLC
2018 Washington, DC, the largest, most recognized international conference in
the world devoted to advances in separation technologies!
More info >> |
|
|
